Table 1 Baseline characteristics of admitted COVID-19 diagnosed patients
From: First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study
Admitted | Admitted to ICU | 30-day follow-up | ||
|---|---|---|---|---|
Variable | Total | Survivors | Non-survivors | |
N (%) | 2431 | 359 (14.8%) | 1976 (81.3%) | 455 (18.7%) |
Age in years, Median (IQR, 25–75%) | 69 (53–80) | 69 (59–75) | 64 (49–77) | 81 (74–86.5) |
Sex (%) | ||||
Female | 1116 (45.9%) | 106 (29.5%) | (47.5%) | 178 (39.1%) |
Male | 1315 (54.1%) | 253 (70.5%) | 1038 (52.5%) | 277 (60.9%) |
Age in age groups, year (%) | ||||
0–64 | 1039 (42.7%) | 135 (37.6%) | 1016 (51.4%) | 23 (5.1%) |
65–84 | 1072 (44.1%) | 212 (59.1%) | 790 (40.0%) | 282 (62.0%) |
85+ | 320 (13.2%) | 12 (3.34%) | 170 (8.6%) | 150 (33.0%) |
Admissions and duration | ||||
Median duration of hospitalizations > 12 h in days (IQR) | 5.47 (2.2–11.11) | 19.38 (10.42–29.05) | 5.19 (1.6–10.55) | 7.02 (3.35–11.48) |
Patients needing | ||||
ICU admission | 359 (14.8%) | 359 (100%) | 252 (12.8%) | 107 (23.5%) |
Mechanical respirator use | 240 (9.9%) | 240 (66.9%) | 167 (8.5%) | 73 (16.0%) |
ECMO | 18 (0.7%) | 18 (5%) | 13 (0.7%) | 5 (1.1%) |
Dialysis | 78 (3.2%) | 78 (21.7%) | 48 (2.4%) | 30 (6.6%) |
Inotropic/Vasopressor use | 210 (8.6%) | 210 (58.5%) | 143 (7.2%) | 67 (14.7%) |
Comorbidities*** | ||||
Any comorbidities | 1475 (60.7%) | 225 (62.7%) | 1086 (55.0%) | 389 (85.5%) |
Cardiovascular disease | ||||
Myocardial infarct | 122 (5%) | 22 (6.1%) | 83 (4.2%) | 39 (8.6%) |
Hypertension | 412 (16.9%) | 55 (15.3%) | 294 (14.9%) | 118 (25.9%) |
Congestive heart failure | 175 (7.2%) | 19 (5.3%) | 114 (5.8%) | 61 (13.4%) |
Peripheral vascular disease | 144 (5.9%) | 30 (8.4%) | 93 (4.7%) | 51 (11.2%) |
Cerebrovascular diseases | 259 (10.7%) | 28 (7.8%) | 176 (8.9%) | 83 (18.2%) |
Chronic respiratory disease | 298 (12.3%) | 45 (12.5%) | 219 (11.1%) | 79 (17.4%) |
Asthma | 122 (5.0%) | 20 (5.6%) | 108 (5.5%) | 14 (3.1%) |
COPD | 216 (8.9%) | 36 (10.0%) | 143 (7.2%) | 73 (16%) |
Immunosuppression | 459 (18.9%) | 84 (23.4%) | 327 (16.5%) | 132 (29%) |
Of which cancer | 324 (13.3%) | 64 (17.8%) | 234 (11.8%) | 90 (19.8%) |
Kidney disease | 130 (5.3%) | 22 (6.1%) | 79 (4.0%) | 51 (11.2%) |
Rheumatologic disease/Connective tissue disease | 104 (4.3%) | 17 (4.7%) | 78 (3.9%) | 26 (5.7%) |
Liver disease | 51 (2.1%) | 10 (2.8%) | 43 (2.2%) | 8 (1.8%) |
Metabolic disease | ||||
Diabetes | 315 (13.0%) | 55 (15.3%) | 225 (11.4%) | 90 (19.8%) |
Obesity | 135 (5.6%) | 23 (6.4%) | 112 (5.7%) | 23 (5.1%) |
Neurological disease | 271 (11.1%) | 38 (10.6%) | 206 (10.4%) | 65 (14.3%) |
Comorbidity level (CCI) | ||||
0 (reference) | 1440 (59.2%) | 201 (56.0%) | 1281 (64.8%) | 159 (34.9%) |
1 to 2 | 703 (28.9%) | 118 (32.9%) | 512 (25.9%) | 191 (42.0%) |
> 2 | 287 (11.8%) | 40 (11.1%) | 182 (9.2%) | 105 (23.1%) |